Related Experiment Video

Updated: Sep 5, 2025

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material
11:12

Optimization of a Multiplex RNA-based Expression Assay Using Breast Cancer Archival Material

Published on: August 1, 2018

8.1K

Expression of Proteinase-activated Receptor 2 (PAR2) as a Correlate of Concern in Triple-negative Breast Cancer

Gargi Kapatia1, Subhpreet Kaur1, Sandeep Kumar2

  • 1Departments of Immunopathology.

Applied Immunohistochemistry & Molecular Morphology : AIMM
|July 7, 2022
PubMed
Abstract

Insights

Proteinase-activated receptor 2 (PAR2) is upregulated in triple-negative breast cancer (TNBC). Higher PAR2 levels correlate with TNBC, indicating its potential as a biomarker or therapeutic target for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies.
  • Identifying specific biomarkers for TNBC remains a critical unmet need.
  • TNBC is characterized by the absence of estrogen, progesterone, and HER2 receptors.

Purpose of the Study:

  • To investigate the expression levels of proteinase-activated receptor 2 (PAR2) in TNBC.
  • To evaluate PAR2 as a potential biomarker or therapeutic target for TNBC.
  • To compare PAR2 expression in TNBC versus non-TNBC subtypes.

Main Methods:

  • Retrospective study of 88 TNBC and 74 non-TNBC patients.
  • Immunohistochemical staining for PAR2 expression.
  • Calculation of PAR2 staining scores based on intensity and percentage positivity.

Main Results:

  • PAR2 levels were significantly upregulated in TNBC compared to non-TNBC.
  • Higher PAR2 expression was observed in TNBC patients over 40 years old.
  • Increased PAR2 expression was associated with lymph node-negative and early-stage TNBC.
  • Lower PAR2 expression was noted in the invasive component of ductal carcinoma.

Conclusions:

  • PAR2 levels are a significant correlate for TNBC.
  • Upregulated PAR2 suggests its potential as a TNBC biomarker.
  • Findings align with studies linking F2RL1 gene expression to poorer TNBC survival.

More Related Videos

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells08:28

Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells

Published on: May 9, 2025

264
Development of Compendium for Esophageal Squamous Cell Carcinoma03:36

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

527

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Receptor Downregulation in MVBs01:15

Receptor Downregulation in MVBs

Multivesicular bodies (MVBs) are mature endosomes that sort ubiquitinated proteins and then fuse with lysosomes to degrade the sorted proteins. Epidermal growth factor (EGF) and its receptor (EGFR) form a complex that can be internalized through endocytosis, sorted into an MVB, and later degraded.
The EGFR can initiate signaling pathways that  lead to cell proliferation, migration, and differentiation. Overexpression of EGFR  stimulates cells to proliferate. Excessive  EGFR...
2.1K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
2.7K
Enzyme-linked Receptors01:00

Enzyme-linked Receptors

Enzyme-linked receptors are proteins that act as both receptor and enzyme, activating multiple intracellular signals. This is a large group of receptors that include the receptor tyrosine kinase (RTK) family. Many growth factors and hormones bind to and activate the RTKs.
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
79.8K